☆ 4.6 Article

Outcome of early treatment of SARS-CoV-2 infection in patients with haematological disorders

BRITISH JOURNAL OF HAEMATOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Immunology

Rapid Selection of Sotrovimab Escape Variants in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron-Infected Immunocompromised Patients

Smaranda Gliga et al.

Summary: Immunocompromised patients infected with Omicron variants experience prolonged viral shedding and the emergence of escape mutations after treatment with sotrovimab. Combination therapy with remdesivir significantly reduces the occurrence of escape variants.

CLINICAL INFECTIOUS DISEASES (2023)

添加到收藏夹

Article Infectious Diseases

ESCMID COVID-19 living guidelines: drug treatment and clinical management

Michele Bartoletti et al.

Summary: This article introduces the establishment and working process of the ESCIMD COVID-19 guidelines task force, and outlines their recommendations for COVID-19 treatment. They provide recommendations for treatment measures, while also pointing out situations where the use of certain drugs is not recommended or should be approached with caution. The article also states that these recommendations are only applicable to adult patients, and emphasizes the backgrounds and limitations of the panel members.

CLINICAL MICROBIOLOGY AND INFECTION (2022)

添加到收藏夹

Letter Oncology

Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience

Barbora Weinbergerova et al.

Summary: COVID-19 significantly impairs survival rates among hematological patients. Our study found that early administration of anti-SARS-CoV-2 spike protein neutralizing monoclonal antibodies can alleviate infection course and decrease mortality. The combination of casirivimab/imdevimab showed a better effect than bamlanivimab monotherapy.

HEMATOLOGICAL ONCOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection A Randomized Clinical Trial

Meagan P. O'Brien et al.

Summary: This study evaluated the effect of subcutaneous casirivimab and imdevimab on progression from asymptomatic SARS-CoV-2 infection to symptomatic COVID-19. The results showed that this combination treatment significantly reduced the incidence of symptomatic COVID-19, as well as the duration of symptoms and viral load.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

添加到收藏夹

Article Medicine, General & Internal

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

A. Jayk Bernal et al.

Summary: This study found that early treatment with molnupiravir reduced the risk of hospitalization or death in at-risk, unvaccinated adults with Covid-19.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

Jennifer Hammond et al.

Summary: In high-risk, unvaccinated adults, treatment of Covid-19 with nirmatrelvir plus ritonavir can significantly reduce the risk of hospitalization and death, with good safety profile.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

R. L. Gottlieb et al.

Summary: In symptomatic, nonhospitalized high-risk Covid-19 patients, a 3-day course of remdesivir significantly reduced the risk of hospitalization or death compared to placebo, with acceptable safety profile.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Oncology

Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies

Christina Y. Lee et al.

Summary: Persistent COVID-19 infection is more likely to occur in patients with hematologic malignancies, particularly B-cell lymphomas. Active therapy and diminished T-cell counts are associated with acute mortality, while B cell-depleting therapy is the main cause of rehospitalization. Patients with persistent infection show high viral entropy, especially those with impaired CD8(+) T-cell immunity. These findings highlight the need for additional therapeutic strategies to clear the virus in immunocompromised patients.

CANCER DISCOVERY (2022)

添加到收藏夹

Article Oncology

Time-Dependent COVID-19 Mortality in Patients With Cancer An Updated Analysis of the OnCovid Registry

David J. Pinato et al.

Summary: This European registry-based study found that the severity and mortality of COVID-19 in cancer patients have improved since the beginning of the pandemic, possibly due to earlier diagnosis, improved management, and dynamic changes in community transmission.

JAMA ONCOLOGY (2022)

添加到收藏夹

Article Immunology

Delayed Mortality Among Solid Organ Transplant Recipients Hospitalized for Coronavirus Disease 2019

Madeleine R. Heldman et al.

Summary: Studies on solid organ transplant recipients hospitalized for COVID-19 show that more than 20% of deaths occur between 28 and 90 days following initial SARS-CoV-2 detection. Risk factors for mortality include age over 65, lung transplant, heart failure, chronic lung disease, and body mass index ≥30 kg/m2.

CLINICAL INFECTIOUS DISEASES (2022)

添加到收藏夹

Editorial Material Infectious Diseases

Immunocompromised patients have been neglected in COVID-19 trials: a call for action

Marius Troseid et al.

CLINICAL MICROBIOLOGY AND INFECTION (2022)

添加到收藏夹

Article Medicine, General & Internal

Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study

Tommy Nyberg et al.

Summary: The Omicron variant shows lower severity compared to Delta, especially in terms of hospital admission and death, with significant variations by age. Unvaccinated cases experience a larger reduction in intrinsic severity, while vaccinated cases experience reduced vaccine effectiveness. Booster vaccination with mRNA vaccines provides over 70% protection against hospitalization and death in breakthrough Omicron infections.

LANCET (2022)

添加到收藏夹

Review Oncology

Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9)

Simone Cesaro et al.

Summary: SARS-CoV-2 infection can lead to severe outcomes in immunocompromised hematological patients, with high mortality rates observed. Treatment strategies focus on controlling viral replication and inflammation. However, the effectiveness and benefits of preventive and therapeutic measures in hematological patients require further investigation.

LEUKEMIA (2022)

添加到收藏夹

Letter Hematology

Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report

Ola Blennow et al.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

添加到收藏夹

Letter Medicine, General & Internal

Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection

Julie Boucau et al.

Summary: The shedding of the culturable SARS-CoV-2 omicron (BA.1) variant could be detected within a median of 8 days after symptom onset or the initial positive test in outpatients with Covid-19, as revealed by frequent PCR and viral-culture assessments.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Letter Medicine, General & Internal

SARS-CoV-2 Evolution and Immune Escape in Immunocompromised Patients

Erin M. Scherer et al.

Summary: This report examines the evolution of SARS-CoV-2 in response to immunologic and monoclonal-antibody pressure in five patients with B-cell deficiency.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Immunology

Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients With Coronavirus Disease-2019 During Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch

Raymund R. Razonable et al.

Summary: This real-world retrospective cohort study demonstrates that there is no significant difference in rates of severe disease progression between bebtelovimab and oral nirmatrelvir-ritonavir treatments for high-risk patients with mild to moderate COVID-19. The use of bebtelovimab is more common among older patients, immunosuppressed patients, and those with multiple comorbid conditions. Despite these comorbid conditions, the rate of progression to severe disease after bebtelovimab treatment is not significantly different from nirmatrelvir-ritonavir treatment.

JOURNAL OF INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages

Shuai Xia et al.

Summary: The Omicron variant and its sublineages exhibit increased transmissibility and immune escape, leading to numerous infections and breakthrough cases.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2022)

添加到收藏夹

Review Public, Environmental & Occupational Health

Understanding viral shedding of severe acute respiratory coronavirus virus 2 (SP Rs-CoV-2): Review of current literature

Lauren M. Fontana et al.

Summary: The study reviewed 77 studies on SARS-CoV-2, finding that viral RNA shedding can last a long time with high heterogeneity, and detection of viral RNA may not correlate with infectivity, requiring further research to determine the shedding of viable virus and its implications for transmission risk.

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2021)

添加到收藏夹

Letter Hematology

Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies

Albrecht Betrains et al.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

添加到收藏夹

Editorial Material Infectious Diseases

Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity Comment

Dafna Yahav et al.

CLINICAL MICROBIOLOGY AND INFECTION (2021)

添加到收藏夹

Article Oncology

COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

Livio Pagano et al.

Summary: This study analyzed baseline characteristics and predictors of mortality in hematological malignancy patients with COVID-19. Results showed that a high percentage of patients developed severe/critical symptoms, with a mortality rate of 31.2%, although improved prevention measures have decreased mortality rates despite an increase in reported cases.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Anil Gupta et al.

Summary: In this study, among nonhospitalized patients with symptomatic Covid-19, sotrovimab treatment significantly reduced the risk of disease progression leading to hospitalization or death compared to placebo. Patients receiving sotrovimab also had a lower rate of serious adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Organ-specific genome diversity of replication-competent SARS-CoV-2

Jolien Van Cleemput et al.

Summary: A detailed virological analysis of thirteen postmortem COVID-19 cases revealed presence of replication-competent SARS-CoV-2 in extrapulmonary organs of immunocompromised patients and identified tissue-specific patterns of genome diversity. Key mutations were found across multiple organs with infectivity confirmed in cell culture. Disease progression was classified into two stages based on duration and viral loads in lungs and plasma.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Immunology

The Longest Persistence of Viable SARS-CoV-2 With Recurrence of Viremia and Relapsing Symptomatic COVID-19 in an Immunocompromised Patient-A Case Study

Chiara Sepulcri et al.

Summary: Immunocompromised patients can have prolonged shedding of SARS-CoV-2 and clinical relapses of COVID-19, with differences in cell immune dynamics and absence of virus-specific antibodies detected.

OPEN FORUM INFECTIOUS DISEASES (2021)

添加到收藏夹

Meeting Abstract Oncology

Outcomes of active cancer patients with COVID-19 infection treated with COVID-19 neutralizing monoclonal antibodies.

Justin Shaya et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Immunology

Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019

Ravindra Ganesh et al.

Summary: This study compared the outcomes of high-risk patients who received bamlanivimab and casirivimab-imdevimab, showing similarly low rates of all-cause and COVID-19-related hospitalizations. Factors associated with higher likelihood of hospitalization included chronic kidney, respiratory, and cardiovascular diseases, as well as immunocompromised status.

JOURNAL OF INFECTIOUS DISEASES (2021)

添加到收藏夹

Editorial Material Medicine, General & Internal

SARS-CoV-2 Variants in Patients with Immunosuppression

Lawrence Corey et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Biophysics

The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy

Per Ljungman et al.

BONE MARROW TRANSPLANTATION (2020)

添加到收藏夹

Article Medicine, General & Internal

COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study

Lennard Y. W. Lee et al.

LANCET (2020)

添加到收藏夹

Article Hematology

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

Francesco Passamonti et al.

LANCET HAEMATOLOGY (2020)

添加到收藏夹

Article Hematology

Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19

Thomas Hueso et al.

BLOOD (2020)

添加到收藏夹

Article Oncology

SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19

Lars F. Westblade et al.

CANCER CELL (2020)

添加到收藏夹

Article Multidisciplinary Sciences

A perspective on potential antibody-dependent enhancement of SARS-CoV-2

Ann M. Arvin et al.

NATURE (2020)

添加到收藏夹

Article Oncology

Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study

Julio Garcia-Suarez et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

添加到收藏夹

Letter Medicine, General & Internal

Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host

Bina Choi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Letter Medicine, General & Internal

Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer

Teresa Aydillo et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.